» Articles » PMID: 36733341

Employing Machine Learning Using Ferroptosis-related Genes to Construct a Prognosis Model for Patients with Osteosarcoma

Overview
Journal Front Genet
Date 2023 Feb 3
PMID 36733341
Authors
Affiliations
Soon will be listed here.
Abstract

Identifying effective biomarkers in osteosarcoma (OS) is important for predicting prognosis. We investigated the prognostic value of ferroptosis-related genes (FRGs) in OS. Transcriptome and clinical data were obtained from The Cancer Genome Atlas and Gene Expression Omnibus. FRGs were obtained from the ferroptosis database. Univariate COX regression and LASSO regression screening were performed and an FRG-based prognostic model was constructed, which was validated using the Gene Expression Omnibus cohort. The predictive power of the model was assessed a subgroup analysis. A nomogram was constructed using clinical markers with independent prognostic significance and risk score results. The CIBERSORT algorithm was used to detect the correlation between prognostic genes and 22 tumor-infiltrating lymphocytes. The expression of prognostic genes in erastin-treated OS cell lines was verified real-time PCR. Six prognostic FRGs ( and ) were obtained and used to construct the risk prognosis model. Subjects were divided into high- and low-risk groups. Prognosis was worse in the high-risk group, and the model had satisfactory prediction performance for patients younger than 18 years, males, females, and those with non-metastatic disease. Univariate COX regression analysis showed that metastasis and risk score were independent risk factors for patients with OS. Nomogram was built on independent prognostic factors with superior predictive power and patient benefit. There was a significant correlation between prognostic genes and tumor immunity. Six prognostic genes were differentially expressed in ferroptosis inducer-treated OS cell lines. The identified prognostic genes can regulate tumor growth and progression by affecting the tumor microenvironment.

Citing Articles

Comprehensive investigation of tumor immune microenvironment and prognostic biomarkers in osteosarcoma through integrated bulk and single-cell transcriptomic analysis.

Shi S, Zhang L, Guo X Front Immunol. 2024; 15:1424950.

PMID: 39108264 PMC: 11300251. DOI: 10.3389/fimmu.2024.1424950.


Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects.

Zeng J, Zhang X, Lin Z, Zhang Y, Yang J, Dou P Exp Hematol Oncol. 2024; 13(1):31.

PMID: 38475936 PMC: 10935897. DOI: 10.1186/s40164-024-00498-3.


A multifunctional biomimetic nanoplatform for image-guideded photothermal-ferroptotic synergistic osteosarcoma therapy.

Liu Y, Dong S, Hu W, Chen Q, Zhang S, Song K Bioact Mater. 2024; 36:157-167.

PMID: 38463554 PMC: 10924166. DOI: 10.1016/j.bioactmat.2024.02.007.


Identification and validation of novel biomarkers associated with immune infiltration for the diagnosis of osteosarcoma based on machine learning.

Ji Y, Lin Z, Li G, Tian X, Wu Y, Wan J Front Genet. 2023; 14:1136783.

PMID: 37732314 PMC: 10507254. DOI: 10.3389/fgene.2023.1136783.

References
1.
Chen M, Jiang Y, Sun Y . KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma. Biochem Biophys Res Commun. 2021; 550:77-83. DOI: 10.1016/j.bbrc.2021.02.137. View

2.
Zhang N, Wang H, Xie Q, Cao H, Wu F, Di Wu D . Identification of potential diagnostic and therapeutic target genes for lung squamous cell carcinoma. Oncol Lett. 2019; 18(1):169-180. PMC: 6539486. DOI: 10.3892/ol.2019.10300. View

3.
Zhao J, Zhao Y, Ma X, Zhang B, Feng H . Targeting ferroptosis in osteosarcoma. J Bone Oncol. 2021; 30:100380. PMC: 8319509. DOI: 10.1016/j.jbo.2021.100380. View

4.
Szabo C, Coletta C, Chao C, Modis K, Szczesny B, Papapetropoulos A . Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc Natl Acad Sci U S A. 2013; 110(30):12474-9. PMC: 3725060. DOI: 10.1073/pnas.1306241110. View

5.
Alfarsi L, El-Ansari R, Craze M, Masisi B, Mohammed O, Ellis I . Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. Int J Mol Sci. 2020; 21(4). PMC: 7073058. DOI: 10.3390/ijms21041407. View